Harnessing the Role of Epigenetic Histone Modification in Targeting Head and Neck Squamous Cell Carcinoma

References

• Allemani C , MatsudaT , DiCarlo Vet al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet391(10125), 1023–1075 (2018).
   PubMed Web of Science ®Google Scholar
• Vigneswaran N , WilliamsMD. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac. Surg. Clin. North Am.26(2), 123–41 (2014).
   PubMed Web of Science ®Google Scholar
• Jethwa AR , KhariwalaSS. Tobacco-related carcinogenesis in head and neck cancer. Cancer Metastasis Rev.36(3), 411–423 (2017).
   PubMed Web of Science ®Google Scholar
• Pai SI , WestraWH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu. Rev. Pathol. Mech. Dis.4, 49–70 (2009).
   PubMed Web of Science ®Google Scholar
• Bray F , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• Borse V , KonwarAN , BuragohainP. Oral cancer diagnosis and perspectives in India. Sensors Int.1, 100046 (2020).
   PubMedGoogle Scholar
• Lund AH , Van LohuizenM. Epigenetics and cancer. Genes Dev.18(19), 36:665–81 (2004).
   Web of Science ®Google Scholar
• Wagner S , SharmaSJ , WuerdemannNet al. Human papillomavirus-related head and neck cancer. Oncol. Res. Treat.28(10), 2386–2398 (2017).
   Google Scholar
• Biswas S , RaoCM. Epigenetic tools (the writers, the readers and the erasers) and their implications in cancer therapy. Eur. J. Pharmacol.837, 8–24 (2018).
   PubMed Web of Science ®Google Scholar
• Crispo F , CondelliV , LeporeSet al. Metabolic dysregulations and epigenetics: a bidirectional interplay that drives tumor progression. Cells8(8), 798 (2019).
   PubMed Web of Science ®Google Scholar
• Castilho RM , SquarizeCH , AlmeidaLO. Epigenetic modifications and head and neck cancer: implications for tumor progression and resistance to therapy. Int. J. Mol. Sci.18(7), 1506 (2017).
   PubMed Web of Science ®Google Scholar
• Le J . Histone modifications: targeting head and neck cancer stem cells. World J. Stem Cells6(5), 511–25 (2014).
   PubMedGoogle Scholar
• Sharma S , KellyTK , JonesPA. Epigenetics in cancer. Carcinogenesis31(1), 27–36 (2009).
   PubMed Web of Science ®Google Scholar
• Lu J , GetzG , MiskaEAet al. MicroRNA expression profiles classify human cancers. Nature435(7043), 834–8 (2005).
   PubMed Web of Science ®Google Scholar
• Rogerio M , CastilhoMDM. Histones: controlling tumor signaling circuitry. J. Carcinog. Mutagen.1(Suppl. 5), 1–12 (2013).
   PubMedGoogle Scholar
• Audia JE , CampbellRM. Histone modifications and cancer. Cold Spring Harb. Perspect. Biol.8(4), a019521 (2016).
   PubMed Web of Science ®Google Scholar
• Kurdistani SK . Histone modifications as markers of cancer prognosis: a cellular view. Br. J. Cancer97(1), 1–5 (2007).
   PubMed Web of Science ®Google Scholar
• Marmorstein R , ZhouMM. Writers and readers of histone acetylation: structure, mechanism, and inhibition. Cold Spring Harb. Perspect. Biol.6(7), a018762 (2014).
   PubMed Web of Science ®Google Scholar
• Lee KK , WorkmanJL. Histone acetyltransferase complexes: one size doesn’t fit all. Nat. Rev. Mol. Cell Biol.8(4), 284–95 (2007).
   PubMed Web of Science ®Google Scholar
• Wang GG , AllisCD , ChiP. Chromatin remodeling and cancer, part I: covalent histone modifications. Trends Mol. Med.13( 9), 363–72 (2007).
   PubMed Web of Science ®Google Scholar
• Gray S , TehB. Histone acetylation/deacetylation and cancer: an ‘open’ and ‘shut’ case?Curr. Mol. Med.1(4), 401–429 (2005).
   Google Scholar
• McBrian MA , BehbahanIS , FerrariRet al. Histone acetylation regulates intracellular pH. Mol. Cell546(7658), 381–386 (2013).
   Google Scholar
• Bais MV . Impact of epigenetic regulation on head and neck squamous cell carcinoma. J. Dent. Res.97(1), 1–5 (2019).
   Google Scholar
• Leonard B , BrandTM , O’KeefeRAet al. BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC. Cancer Res.78(15), 4331–4343 (2018).
   PubMed Web of Science ®Google Scholar
• Seto E , YoshidaM. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb. Perspect. Biol.6(4), a018713 (2014).
   PubMed Web of Science ®Google Scholar
• Milazzo G , MercatelliD , DiMuzio Get al. Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability. Genes (Basel)11(5), 556 (2020).
   PubMed Web of Science ®Google Scholar
• Chang HH , ChiangCP , HungHC , LinCY , DengYT , KuoMYP. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol.45(7), 610–4 (2009).
   PubMed Web of Science ®Google Scholar
• Sakuma T , UzawaK , OndaTet al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int. J. Oncol.29(1), 117–24 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen I , PorȩbaE , KamieniarzK , SchneiderR. Histone modifiers in cancer: friends or foes?Genes Cancer2(6), 631–47 (2011).
   PubMedGoogle Scholar
• Gaździcka J , GołąbekK , StrzelczykJK , OstrowskaZ. Epigenetic modifications in head and neck cancer. Biochem. Genet.58(2), 213–244 (2020).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo A , BedfordMT. Histone arginine methylation. FEBS Lett.585(13), 2024–31 (2011).
   PubMed Web of Science ®Google Scholar
• Hyun K , JeonJ , ParkK , KimJ. Writing, erasing and reading histone lysine methylations. Exp. Mol. Med.49(4), e324 (2017).
   PubMed Web of Science ®Google Scholar
• Saloura V , VougiouklakisT , SieversCet al. The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck. Oral Oncol.81, 100–108 (2018).
   PubMed Web of Science ®Google Scholar
• Handy DE , CastroR , LoscalzoJ. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation19(2), 169–74 (2011).
   Google Scholar
• Zhang T , CooperS , BrockdorffN. The interplay of histone modifications – writers that read. EMBO Rep.16(11), 1467–81 (2015).
   PubMed Web of Science ®Google Scholar
• Kidani K , OsakiM , TamuraTet al. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol.45(1), 39–46 (2009).
   PubMed Web of Science ®Google Scholar
• Mancuso M , MatassaDS , ConteMet al. H3K4 histone methylation in oral squamous cell carcinoma. Acta Biochim. Pol.56(3), 405–10 (2009).
   PubMed Web of Science ®Google Scholar
• Chen JH , YehKT , YangYM , ChangJG , LeeHE , HungSY. High expressions of histone methylation- and phosphorylation-related proteins are associated with prognosis of oral squamous cell carcinoma in male population of Taiwan. Med. Oncol.30(2), 513 (2013).
   PubMed Web of Science ®Google Scholar
• Soto D , SongC , McLaughlin-DrubinME. Epigenetic alterations in human papillomavirus-associated cancers. Viruses9(9), 248 (2017).
   PubMed Web of Science ®Google Scholar
• Oki M , AiharaH , ItoT. Role of histone phosphorylation in chromatin dynamics and its implications in diseases. Subcell. Biochem.41, 319–36 (2007).
   PubMedGoogle Scholar
• Rossetto D , AvvakumovN , CôtéJ. Histone phosphorylation: a chromatin modification involved in diverse nuclear events. Epigenetics7(10), 1098–108 (2012).
   PubMed Web of Science ®Google Scholar
• Wu M , KafanasA , GanLet al. Feasibility of immunocytochemical detection of tumor markers (XIAP, phosphohistone H1 and p63) in FNA cellblock samples from head and neck squamous cell carcinoma. Diagn. Cytopathol.36(11), 797–800 (2008).
   PubMed Web of Science ®Google Scholar
• Jessri M , DalleyAJ , FarahCS. Deficient double-strand break repair in oral squamous cell carcinoma cell lines. J. Oral Pathol. Med.46(9), 695–702 (2017).
   PubMed Web of Science ®Google Scholar
• Podhorecka M , SkladanowskiA , BozkoP. H2AX phosphorylation: its role in DNA damage response and cancer therapy. J. Nucleic Acids2010, 920161 (2010).
   PubMedGoogle Scholar
• Lee JW , ParameswaranJ , Sandoval-SchaeferTet al. Combined Aurora kinase A (AURKA) and WEE1 inhibition demonstrates synergistic antitumor effect in squamous cell carcinoma of the head and neck. Clin. Cancer Res.25(11), 3430–3442 (2019).
   PubMed Web of Science ®Google Scholar
• Hoellein A , PickhardA , von KeitzFet al. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget2(8), 599–609 (2011).
   PubMedGoogle Scholar
• Pannone G , HindiSAH , SantoroAet al. Aurora B expression as a prognostic indicator and possibile therapeutic target in oral squamous cell carcinoma. Int. J. Immunopathol. Pharmacol.24(1),79–88 (2011).
   PubMed Web of Science ®Google Scholar
• Qi G , OgawaI , KudoYet al. Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch.450(3), 297–302 (2007).
   PubMed Web of Science ®Google Scholar
• Gallo LH , KoJ , DonoghueDJ. The importance of regulatory ubiquitination in cancer and metastasis. Cell Cycle16(7),634–648 (2017).
   PubMed Web of Science ®Google Scholar
• Deng L , MengT , ChenL , WeiW , WangP. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct. Target. Ther.5(1), 11 (2020).
   PubMed Web of Science ®Google Scholar
• Jones PA , BaylinSB. The epigenomics of cancer. Cell (2007).
   Google Scholar
• Füllgrabe J , KavanaghE , JosephB. Histone onco-modifications. Oncogene30(31), 3391–403 (2011).
   PubMed Web of Science ®Google Scholar
• Khammanivong A , GopalakrishnanR , DickersonEB. SMURF1 silencing diminishes a CD44-high cancer stem cell-like population in head and neck squamous cell carcinoma. Mol. Cancer13, 260 (2014).
   PubMed Web of Science ®Google Scholar
• Shema E , TiroshI , AylonYet al. Corrigendum: the histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Genes Dev.31(18), 1926 (2017).
   PubMed Web of Science ®Google Scholar
• Redon CE , NakamuraAJ , ZhangYWet al. Histone γH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin. Cancer Res.16(18),4532–42 (2010).
   PubMed Web of Science ®Google Scholar
• Das BR . Increased ADP-ribosylation of histones in oral cancer. Cancer Lett.73(1), 29–34 (1993).
   PubMed Web of Science ®Google Scholar
• Yang H , JinX , DanH , ChenQ. Histone modifications in oral squamous cell carcinoma and oral potentially malignant disorders. Oral Dis.26(4), 719–732 (2020).
   PubMed Web of Science ®Google Scholar
• Kassab MA , YuLL , YuX. Targeting dePARylation for cancer therapy. Cell Biosci.107 (2020).
   PubMed Web of Science ®Google Scholar
• Moody CA , LaiminsLA. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer10(8), 550–60 (2010).
   PubMed Web of Science ®Google Scholar
• Pullos AN , CastilhoRM , SquarizeCH. HPV infection of the head and neck region and its stem cells. J. Dent. Res.94(11), 1532–43 (2015).
   PubMed Web of Science ®Google Scholar
• Low GM , ThylurDS , YamamotoV , SinhaUK. The effect of human papillomavirus on DNA repair in head and neck squamous cell carcinoma. Oral Oncol.61, 27–30 (2016).
   PubMed Web of Science ®Google Scholar
• Stransky N , EgloffAM , TwardADet al. The mutational landscape of head and neck squamous cell carcinoma. Science333(6046), 1157–60 (2011).
   PubMed Web of Science ®Google Scholar
• Melle C , ErnstG , WinklerRet al. Proteomic analysis of human papillomavirus-related oral squamous cell carcinoma: identification of thioredoxin and epidermal-fatty acid binding protein as upregulated protein markers in microdissected tumor tissue. Proteomics9(8),2193–2012009).
   PubMed Web of Science ®Google Scholar
• Nulton TJ , OlexAL , DozmorovM , MorganIM , WindleB.Analysis of The Cancer Genome Atlas sequencing data reveals novel properties of the human papillomavirus 16 genome in head and neck squamous cell carcinoma. Oncotarget8(11), 17684–17699 (2017).
   PubMedGoogle Scholar
• Mooren JJ , KremerB , ClaessenSMHet al. Chromosome stability in tonsillar squamous cell carcinoma is associated with HPV16 integration and indicates a favorable prognosis. Int. J. Cancer132(8), 1781–9 (2013).
   PubMed Web of Science ®Google Scholar
• Boscolo-Rizzo P , FurlanC , LupatoV , PoleselJ , FrattaE. Novel insights into epigenetic drivers of oropharyngeal squamous cell carcinoma: role of HPV and lifestyle factors. Clin. Epigenetics9, 124 (2017).
   PubMed Web of Science ®Google Scholar
• Durzynska J , LesniewiczK , PorebaE. Human papillomaviruses in epigenetic regulations. Mutat. Res. Rev. Mutat. Res.772, 36–50 (2017).
   PubMed Web of Science ®Google Scholar
• Patel D , HuangSM , BagliaLA , McCanceDJ. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J.18(18), 5061–72 (1999).
   PubMed Web of Science ®Google Scholar
• Bernat A , AvvakumovN , MymrykJS , BanksL. Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene22(39),7871–81 (2003).
   PubMed Web of Science ®Google Scholar
• Thomas MC , ChiangCM. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol. Cell17(2),251–64 (2005).
   PubMed Web of Science ®Google Scholar
• Hasan UA , ZannettiC , ParrochePet al. The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J. Exp. Med.210(7),1369–87 (2013).
   PubMed Web of Science ®Google Scholar
• Park JS , KimEJ , KwonHJ , HwangES , NamkoongSE , UmSJ. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J. Biol. Chem.275(10), 6764–9 (2000).
   PubMed Web of Science ®Google Scholar
• Dok R , NuytsS. HPV positive head and neck cancers: molecular pathogenesis and evolving treatment strategies. Cancers (Basel)8(4), 41 (2016).
   PubMed Web of Science ®Google Scholar
• Majchrzak E , SzybiakB , WegnerAet al. Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature. Radiol. Oncol.48(1), 1–10 (2014).
   PubMed Web of Science ®Google Scholar
• Boscolo-Rizzo P , DelMistro A , BussuFet al. New insights into human papillomavirus-associated head and neck squamous cell carcinoma. Acta Otorhinolaryngol. Ital.33(2), 77–87 (2013).
   PubMed Web of Science ®Google Scholar
• Deschler DG , RichmonJD , KhariwalaSS , FerrisRL , WangMB. The ‘new’ head and neck cancer patient – young, nonsmoker, nondrinker, and HPV positive: evaluation. Otolaryngol. Head Neck Surg.151(3), 375–80 (2014).
   PubMed Web of Science ®Google Scholar
• Lewis A , KangR , LevineA , MaghamiE. The new face of head and neck cancer: the HPV epidemic. Oncology (Williston Park)29(9), 616–26 (2015).
   PubMed Web of Science ®Google Scholar
• Economopoulou P , KotsantisI , PsyrriA. Special issue about head and neck cancers: HPV positive cancers. Int. J. Mol. Sci.21(9), 3388 (2020).
   PubMed Web of Science ®Google Scholar
• Kobayashi K , HisamatsuK , SuzuiN , HaraA , TomitaH , MiyazakiT. A review of HPV-related head and neck cancer. J. Clin. Med.7(9), 241 (2018).
   PubMed Web of Science ®Google Scholar
• Gunduz M , GunduzE , TamagawaS , EnomotoK , HotomiM. Identification and chemoresistance of cancer stem cells in HPV-negative oropharyngeal cancer. Oncol. Lett.1, 965–971 (2020).
   Google Scholar
• Alsahafi E , BeggK , AmelioIet al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis.10(8), 540 (2019).
   PubMedGoogle Scholar
• Pickering CR , ZhangJ , YooSYet al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov.3(7), 770–81 (2013).
   PubMed Web of Science ®Google Scholar
• Heerboth S , LapinskaK , SnyderN , LearyM , RollinsonS , SarkarS. Use of epigenetic drugs in disease: an overview. Genet. Epigenetics6, 9–19 (2014).
   PubMedGoogle Scholar
• Mithraprabhu S , KalffA , ChowA , KhongT , SpencerA. Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics9(11), 1511–20 (2014).
   PubMed Web of Science ®Google Scholar
• He L , GaoL , ShayC , LangL , LvF , TengY. Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR–ARF1 axis. J. Exp. Clin. Cancer Res.38(1), 84 (2019).
   PubMedGoogle Scholar
• Mann BS , JohnsonJR , CohenMH , JusticeR , PazdurR. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist12(10), 1247–52 (2007).
   PubMed Web of Science ®Google Scholar
• Grabarska A , LuszczkiJJ , NowosadzkaEet al. Histone deacetylase inhibitor SAHA as potential targeted therapy agent for larynx cancer cells. J. Cancer8(1), 19–28 (2017).
   PubMed Web of Science ®Google Scholar
• Haigentz M , KimM , SartaCet al. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol.48(12), 1281–1288 (2012).
   PubMed Web of Science ®Google Scholar
• Blumenschein GR , KiesMS , PapadimitrakopoulouVAet al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest. New Drugs26(1), 81–87 (2008).
   PubMed Web of Science ®Google Scholar
• Pan CH , ChangYF , LeeMSet al. Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells. BMC Cancer16(1), 857 (2016).
   PubMedGoogle Scholar
• Teknos TN , GreculaJ , AgrawalAet al. A phase 1 trial of vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. Invest. New Drugs37(4), 702–710 (2019).
   PubMed Web of Science ®Google Scholar
• Suraweera A , O’ByrneKJ , RichardDJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front. Oncol.8, 92 (2018).
   PubMed Web of Science ®Google Scholar
• Citro S , BelliniA , MiccoloC , GhianiL , CareyTE , ChioccaS. Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α. Br. J. Cancer120(6), 658–667 (2019).
   PubMed Web of Science ®Google Scholar
• Weng CH , ChenLY , LinYCet al. Epithelial–mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene38(4), (2019).
   Web of Science ®Google Scholar
• Jeannot V , BusserB , VanwonterghemLet al. Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. Onco. Targets Ther.9, 6843–6855 (2016).
   PubMed Web of Science ®Google Scholar
• Avallone A , PiccirilloMC , DiGennaro Eet al. Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol. Ther. Adv. Med. Oncol.12, 1758835920929589 (2020).
   Web of Science ®Google Scholar
• Erlich RB , RickwoodD , ComanWB , SaundersNA , GuminskiA. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Cancer Chemother. Pharmacol.16(),1421–1434 (2009).
   Google Scholar
• Budillon A , ZottiAI , VitaglianoC , DiGennaro E , CaponigroF. Preclinical and phase-2 clinical study of valproic acid administered in combination with cisplatin and cetuximab in recurrent/metastatic head and neck cancere. Exp. Mol. Ther.77(13), :4058 (2017).
   Google Scholar
• Yu C , ZhuangS. Histone methyltransferases as therapeutic targets for kidney diseases. Front. Pharmacol.10, 1393 (2019).
   PubMed Web of Science ®Google Scholar
• Rugo HS , JacobsI , SharmaSet al. The promise for histone methyltransferase inhibitors for epigenetic therapy in clinical oncology: a narrative review. Adv. Ther.37(7), 3059–3082 (2020).
   PubMed Web of Science ®Google Scholar
• Liu CW , HuaKT , LiKCet al. Histone methyltransferase G9a drives chemotherapy resistance by regulating the glutamate–cysteine ligase catalytic subunit in head and neck squamous cell carcinoma. Mol. Cancer Ther.16(7), 1421–1434 (2017).
   PubMed Web of Science ®Google Scholar
• Xu B , KonzeKD , JinJ , WangGG. Targeting EZH2 and PRC2 dependence as novel anticancer therapy. Exp. Hematol.43(8), 698–712 (2015).
   PubMed Web of Science ®Google Scholar
• Bourguignon LYW , WongG , ShiinaM. Up-regulation of histone methyltransferase, DOT1L, by matrix hyaluronan promotes microRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma. J. Biol. Chem.291(20), 10571–85 (2016).
   PubMed Web of Science ®Google Scholar
• Selvi RB , SwaminathanA , ChatterjeeSet al. Inhibition of p300 lysine acetyltransferase activity by luteolin reduces tumor growth in head and neck squamous cell carcinoma (HNSCC) xenograft mouse model. Oncotarget6(41), 43806–18 (2015).
   PubMedGoogle Scholar
• Li F , ShanmugamMK , SiveenKSet al. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers. Oncotarget6(7), 5147–53 (2015).
   PubMedGoogle Scholar
• Kumar B , YadavA , LangJC , TeknosTN , KumarP. Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog. Genes Cancer6(3-4), 169–81 (2015).
   PubMedGoogle Scholar
• Gailhouste L , LiewLC , HatadaI , NakagamaH , OchiyaT. Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells. Cell Death Dis.9(5), 468 (2018).
   PubMedGoogle Scholar
• Biktasova A , HajekM , SewellAet al. Demethylation therapy as a targeted treatment for human papillomavirus-associated head and neck cancer. Clin. Cancer Res.23(23), 7276–7287 (2017).
   PubMed Web of Science ®Google Scholar
• Gnyszka A , JastrzȩbskiZ , FlisS. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res.33(8), 2989–2986 (2013).
   PubMed Web of Science ®Google Scholar